Tumor immune profiling predicts response to anti–PD-1 therapy in human melanoma
Open accessThe DOI matches its Crossref record; 22 of the 23 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Immune checkpoint blockade is revolutionizing therapy for advanced cancer, but many patients do not respond to treatment. The identification of robust biomarkers that predict clinical response to specific checkpoint inhibitors is critical in order to stratify patients and to rationally select combinations in the context of an expanding array of therapeutic options. METHODS: We performed multiparameter flow cytometry on freshly isolated metastatic melanoma samples from 2 cohorts of 20 patients each prior to treatment and correlated the subsequent clinical response with the tumor immune phenotype. RESULTS: Increasing fractions of programmed cell death 1 high/cytotoxic T lymphocyte-associated protein 4 high (PD-1hiCTLA-4hi) cells within the tumor-infiltrating CD8+ T cell subset strongly correlated with response to therapy (RR) and progression-free survival (PFS). Functional analysis of these cells revealed a partially exhausted T cell phenotype. Assessment of metastatic lesions during anti-PD-1 therapy demonstrated a release of T cell exhaustion, as measured by an accumulation of highly activated CD8+ T cells within tumors, with no effect on Tregs. CONCLUSIONS: Our data suggest that the relative abundance of partially exhausted tumor-infiltrating CD8+ T cells predicts response to anti-PD-1 therapy. This information can be used to appropriately select patients with a high likelihood of achieving a clinical response to PD-1 pathway inhibition. FUNDING: This work was funded by a generous gift provided by Inga-Lill and David Amoroso as well as a generous gift provided by Stephen Juelsgaard and Lori Cook.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“the presence of CD8 + PD-1 hi T cells in the tumors of patients with melanoma and patients with NSCLC prior to anti-PD-1 administration was predictive of treatment response and correlated with overall survival (146, 147).”
From Immune Checkpoint Inhibitors for the Treatment of Cancer: Clinical Impact and Mechanisms of Response and Resistance (2021) · cites this paper as [146]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay-Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,256
PD-1 blockade induces responses by inhibiting adaptive immune resistance
Tumeh, P. C., Harview, C. L., Yearley, J. H., Shintaku, I. P., Taylor, E. J. M., Robert, L., Chmielowski, B., Spasic, M., Henry, G., Ciobanu, V., et al. (2014) · Nature · doi:10.1038/nature13954 · Cited by 6,609
Self-citationPredictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients
Herbst, R. S., Soria, J.-C., Kowanetz, M., Fine, G. D., Hamid, O., Gordon, M. S., Sosman, J. A., McDermott, D. F., Powderly, J. D., Gettinger, S. N., et al. (2014) · Nature · doi:10.1038/nature14011 · Cited by 5,231
Wherry, E. J. (2011) · Nature Immunology · doi:10.1038/ni.2035 · Cited by 4,062
Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma
Hamid, O., Robert, C., Daud, A., Hodi, F. S., Hwu, W.-J., Kefford, R., Wolchok, J. D., Hersey, P., Joseph, R. W., Weber, J. S., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1305133 · Cited by 3,392
Self-citationBrahmer, J. R., Drake, C. G., Wollner, I., Powderly, J. D., Picus, J., Sharfman, W. H., Stankevich, E., Pons, A., Salay, T. M., McMiller, T. L., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.26.7609 · Cited by 2,961
PD-L1 expression as a predictive biomarker in cancer immunotherapy
Patel, S. P., & Kurzrock, R. (2015) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-14-0983 · Cited by 2,291
Ahmadzadeh, M., Johnson, L. A., Heemskerk, B., Wunderlich, J. R., Dudley, M. E., White, D. E., & Rosenberg, S. A. (2009) · Blood · doi:10.1182/blood-2008-12-195792 · Cited by 1,766
Rizvi, N. A., Mazières, J., Planchard, D., Stinchcombe, T. E., Dy, G. K., Antonia, S. J., Horn, L., Lena, H., Minenza, E., Mennecier, B., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)70054-9 · Cited by 1,415
Cited by
Items 201–300 of 528
Robust prediction of clinical outcomes using cytometry data
Hu, Z., Glicksberg, B. S., & Butte, A. J. (2018) · Bioinformatics · doi:10.1093/bioinformatics/bty768 · Cited by 36
Inomata, M., Kado, T., Okazawa, S., Imanishi, S., Taka, C., Kambara, K., Hirai, T., Tanaka, H., Tokui, K., Hayashi, K., et al. (2019) · Anticancer Research · doi:10.21873/anticanres.13908 · Cited by 41
The role of sex in the innate and adaptive immune environment of metastatic colorectal cancer
Ray, A. L., Nofchissey, R. A., Khan, M. A., Reidy, M. A., Lerner, M. R., Wu, X., Guo, S., Hill, S. L., Weygant, N., Adams, S. F., et al. (2020) · British Journal of Cancer · doi:10.1038/s41416-020-0913-8 · Cited by 43
Targeting inflamed and non-inflamed melanomas: biological background and clinical challenges
Indini, A., Massi, D., Pirro, M., Roila, F., Grossi, F., Sahebkar, A., Glodde, N., Bald, T., & Mandalà, M. (2022) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2022.06.005 · Cited by 42
Marderstein, A. R., Uppal, M., Verma, A., Bhinder, B., Tayyebi, Z., Mezey, J. G., Clark, A. G., & Elemento, O. (2020) · Nature Communications · doi:10.1038/s41467-020-16097-9 · Cited by 39
Long-Term Outcomes of Immune Checkpoint Inhibition in Metastatic Melanoma
Aroldi, F., & Middleton, M. R. (2022) · American Journal of Clinical Dermatology · doi:10.1007/s40257-022-00681-4 · Cited by 36
Immune Checkpoint Inhibitors for Treating Advanced Cutaneous Squamous Cell Carcinoma
Patel, R., & Chang, A. L. S. (2019) · American Journal of Clinical Dermatology · doi:10.1007/s40257-019-00426-w · Cited by 34
Prenzler, S., Rudrawar, S., Waespy, M., Kelm, S., Anoopkumar‐Dukie, S., & Haselhorst, T. (2021) · International Reviews of Immunology · doi:10.1080/08830185.2021.1931171 · Cited by 46
Tumor Infiltrating Lymphocyte Expression of PD-1 Predicts Response to Anti-PD-1/PD-L1 Immunotherapy
Bevins, N., Okamura, R., Montesion, M., Adashek, J. J., Goodman, A. M., & Kurzrock, R. (2022) · Journal of Immunotherapy and Precision Oncology · doi:10.36401/jipo-22-9 · Cited by 45
Predictive factors of response to immunotherapy—a review from the Spanish Melanoma Group (GEM)
On behalf of the Spanish Melanoma Group (GEM), Espinosa, E., Márquez‐Rodas, I., Soria, A., Berrocal, A., Manzano, J. L., González‐Cao, M., & Martín‐Algarra, S. (2017) · Annals of Translational Medicine · doi:10.21037/atm.2017.08.10 · Cited by 37
SITC cancer immunotherapy resource document: a compass in the land of biomarker discovery
Hu‐Lieskovan, S., Bhaumik, S., Dhodapkar, K. M., Grivel, J., Gupta, S. V., Hanks, B. A., Janetzki, S., Kleen, T. O., Koguchi, Y., Lund, A. W., et al. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-000705 · Cited by 41
Find the Flame: Predictive Biomarkers for Immunotherapy in Melanoma
Garutti, M., Bonin, S., Buriolla, S., Bertoli, E., Pizzichetta, M. A., Zalaudek, I., & Puglisi, F. (2021) · Cancers · doi:10.3390/cancers13081819 · Cited by 38
Biomarkers related to immune checkpoint inhibitors therapy
Li, N., Hou, X., Huang, S., Tai, R., Lei, L., Li, S., Abuliz, A., Wang, G., & Yang, S. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2021.112470 · Cited by 37
Campana, L. G., DAUD, A. I., Lancellotti, F., Arroyo, J. P., Davalos, R. V., Prata, C. D., & Gehl, J. (2023) · Cancers · doi:10.3390/cancers15133340 · Cited by 36
Self-citationImmune Checkpoint Ligand Reverse Signaling: Looking Back to Go Forward in Cancer Therapy
Lecis, D., Sangaletti, S., Colombo, M. P., & Chiodoni, C. (2019) · Cancers · doi:10.3390/cancers11050624 · Cited by 37
Neoadjuvant therapy alters the immune microenvironment in pancreatic cancer
Zhang, H., Ye, L., Yu, X., Jin, K., & Wu, W. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.956984 · Cited by 39
Andrews, M. C., Reuben, A., Gopalakrishnan, V., & Wargo, J. A. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.00946 · Cited by 35
van Dinther, D., Venegas, M. L., Veninga, H., Olesek, K., Hoogterp, L., Revet, M., Ambrosini, M., Kalay, H., Stöckl, J., van Kooyk, Y., et al. (2019) · Cancers · doi:10.3390/cancers11020183 · Cited by 34
Li, R., Zhang, H., Cao, Y., Liu, X., Chen, Y., Qi, Y., Wang, J., Yu, K., Lin, C., Liu, H., et al. (2020) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-020-02550-7 · Cited by 37
Fietz, S., Zarbl, R., Niebel, D., Posch, C., Brossart, P., Gielen, G. H., Strieth, S., Pietsch, T., Kristiansen, G., Bootz, F., et al. (2020) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-020-02777-4 · Cited by 36
Opportunities and challenges to engineer 3D models of tumor-adaptive immune interactions
Visalakshan, R. M., Lowrey, M. K., Sousa, M. G. C., Helms, H. R., Samiea, A., Schutt, C. E., Moreau, J. M., & Bertassoni, L. E. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1162905 · Cited by 35
Comparative analysis of immune infiltrates in head and neck cancers across anatomical sites
Muijlwijk, T., Nijenhuis, D. N. L. M., Ganzevles, S. H., Brink, A., Ke, C., Fass, J. N., Rajamanickam, V., Leemans, C. R., Koguchi, Y., Fox, B. A., et al. (2024) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2023-007573 · Cited by 37
Burkart, C., Mukhopadhyay, A., Shirley, S. A., Connolly, R. J., Wright, J. H., Bahrami, A. J., Campbell, J. S., Pierce, R. H., & Canton, D. A. (2018) · Gene Therapy · doi:10.1038/s41434-018-0006-y · Cited by 33
Self-citationPhenotype molding of T cells in colorectal cancer by single‐cell analysis
Di, J., Liu, M., Fan, Y., Gao, P., Wang, Z., Jiang, B., & Su, X. (2020) · International Journal of Cancer · doi:10.1002/ijc.32856 · Cited by 37
Sphingosine kinase 1 promotes tumor immune evasion by regulating the MTA3-PD-L1 axis
Lau, P., Zhang, G., Zhao, S., Liang, L., Zhang, H., Zhou, G., Hung, M., Chen, X., & Liu, H. (2022) · Cellular and Molecular Immunology · doi:10.1038/s41423-022-00911-z · Cited by 38
Heller, S. R., Glaeske, S., Gluske, K., Paul, J., Böhme, A., Janzer, A., Roider, H. G., Montebaur, A., Nicke, B., Lesche, R., et al. (2023) · Clinical and Experimental Medicine · doi:10.1007/s10238-023-01227-6 · Cited by 43
Cell-Mediated Immunity to Target the Persistent Human Immunodeficiency Virus Reservoir
Riley, J. L., & Montaner, L. J. (2017) · The Journal of Infectious Diseases · doi:10.1093/infdis/jix002 · Cited by 30
Jansen, C. S., Prokhnevska, N., & Kissick, H. T. (2018) · Urologic Oncology Seminars and Original Investigations · doi:10.1016/j.urolonc.2018.10.011 · Cited by 35
Predictive biomarkers of response to immune checkpoint inhibitors in melanoma
Nebhan, C. A., & Johnson, D. B. (2020) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2020.1724539 · Cited by 32
You, W., Shang, B., Sun, J., Liu, X., Su, L., & Jiang, S. (2020) · Oncology Reports · doi:10.3892/or.2020.7643 · Cited by 36
SLAMF8 expression predicts the efficacy of anti‐PD1 immunotherapy in gastrointestinal cancers
Zhang, Q., Cheng, L., Qin, Y., Kong, L., Shi, X., Hu, J. Y., Li, L., Ding, Z., Wang, T., Shen, J., et al. (2021) · Clinical & Translational Immunology · doi:10.1002/cti2.1347 · Cited by 31
Naing, A., Infante, J. R., Goel, S., Burris, H. A., Black, C., Marshall, S. A., Achour, I., Barbee, S. D., May, R., Morehouse, C., et al. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0665-2 · Cited by 33
Elia, A. R., Caputo, S., & Bellone, M. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.01786 · Cited by 32
Khushalani, N. I., Diab, A. K., Ascierto, P. A., Larkin, J., Sandhu, S. K., Sznol, M., Koon, H. B., Jarkowski, A., Zhou, M., Statkevich, P., et al. (2020) · Future Oncology · doi:10.2217/fon-2020-0351 · Cited by 31
Prognostic and predictive biomarkers in melanoma
Maher, N. G., Vergara, I. A., Long, G. V., & Scolyer, R. A. (2023) · Pathology · doi:10.1016/j.pathol.2023.11.004 · Cited by 39
Zhu, Y., Zhao, F., Li, Z., & Yu, J. (2018) · Cancer Management and Research · doi:10.2147/cmar.s167400 · Cited by 30
JiaWei, Z., ChunXia, D., CunDong, L., Liu, Y., JianKun, Y., HaiFeng, D., Yang, C., ZhiPeng, H., Hongyi, W., DeYing, L., et al. (2021) · Annals of Medicine · doi:10.1080/07853890.2021.1924396 · Cited by 35
Serum Amyloid A Proteins and Their Impact on Metastasis and Immune Biology in Cancer
Lee, J., & Beatty, G. L. (2021) · Cancers · doi:10.3390/cancers13133179 · Cited by 30
Adegoke, N. A., Gide, T. N., Mao, Y., Quek, C. Y. J., Patrick, E., Carlino, M. S., Lo, S., Menzies, A. M., da Silva, I. P., Vergara, I. A., et al. (2023) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2023-007144 · Cited by 34
Turkington, R. C., Knight, L. A., Blayney, J. K., Secrier, M., Douglas, R. V., Parkes, E. E., Sutton, E. K., Stevenson, L. S., McManus, D. T., Halliday, S. R., et al. (2019) · Gut · doi:10.1136/gutjnl-2018-317624 · Cited by 28
Zhang, Y., Liu, B., Kotenko, S. V., & Li, W. (2022) · Medicine · doi:10.1097/md.0000000000029536 · Cited by 33
Molecular predictors of response to PD-1/PD-L1 inhibition in urothelial cancer
Stühler, V., Maas, J. M., Bochem, J., da Costa, I. A., Todenhöfer, T., Stenzl, A., & Bedke, J. (2018) · World Journal of Urology · doi:10.1007/s00345-018-2538-6 · Cited by 28
T-cell therapy for chronic viral hepatitis
Bertoletti, A., Tan, A. T., & Koh, S. (2017) · Cytotherapy · doi:10.1016/j.jcyt.2017.07.011 · Cited by 31
Herbreteau, G., Vallée, A., Knol, A., Théoleyre, S., Quereux, G., Varey, É., Khammari, A., Dréno, B., & Denis, M. G. (2021) · Cancers · doi:10.3390/cancers13081826 · Cited by 31
Pour, S. R., de Coaña, Y. P., Demorentin, X. M., Melief, J., Thimma, M., Wolodarski, M., Gómez-Cabrero, D., Hansson, J., Kiessling, R. W., & Tegner, J. N. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-002171 · Cited by 27
Lin, X., Dong, L., Yan, Q., Dong, Y., Wang, L., & Wang, F. (2022) · Foods · doi:10.3390/foods11213507 · Cited by 29
Weiss, S. A., Zito, C. R., Tran, T. T. T., Heishima, K., Neumeister, V. M., McGuire, J., Adeniran, A., Kluger, H. M., & Jilaveanu, L. B. (2020) · Journal of Neuro-Oncology · doi:10.1007/s11060-020-03619-0 · Cited by 26
CD8+ T-cell exhaustion: Impediment to triple-negative breast cancer (TNBC) immunotherapy
Feng, D., Pu, D., Ren, J., Liu, M., Zhang, Z., Liu, Z., & Li, J. (2024) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2024.189193 · Cited by 33
Review of biomarkers for response to immunotherapy in HNSCC microenvironment
Chen, S., Yang, Y., He, S., Lian, M., Wang, R., & Fang, J. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1037884 · Cited by 34
Combination immunotherapies implementing adoptive T-cell transfer for advanced-stage melanoma
Foley, K. C., Nishimura, M. I., & Moore, T. V. (2018) · Melanoma Research · doi:10.1097/cmr.0000000000000436 · Cited by 29
Singh, S. D., Singh, N., Baranwal, M., Sharma, S., Devi, S., & Kumar, S. (2023) · 3 Biotech · doi:10.1007/s13205-023-03826-2 · Cited by 27
Cerapio, J., Perrier, M., Balança, C.-C., Gravelle, P., Pont, F., Devaud, C., Franchini, D., Féliu, V., Tosolini, M., Valle, C., et al. (2021) · OncoImmunology · doi:10.1080/2162402x.2021.1939518 · Cited by 29
Intratumoral therapies and in-situ vaccination for melanoma
Huppert, L. A., & DAUD, A. I. (2022) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2021.1890512 · Cited by 27
Self-citationPéricart, S., Tosolini, M., Gravelle, P., Rossi, C., Traverse‐Glehen, A., Amara, N., Franchet, C., Martin, E., Bezombes, C., Laurent, G., et al. (2018) · Cancers · doi:10.3390/cancers10110415 · Cited by 26
Mastracci, L., Fontana, V., Queirolo, P., Carosio, R., Grillo, F., Morabito, A., Banelli, B., Tanda, E. T., Boutros, A., Dozin, B., et al. (2020) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-020-02494-y · Cited by 28
Tumor core biopsies adequately represent immune microenvironment of high-grade serous carcinoma
Lara, O. D., Krishnan, S., Wang, Z., Corvigno, S., Zhong, Y., Lyons, Y., Dood, R. L., Hu, W., Qi, L., Liu, J., et al. (2019) · Scientific Reports · doi:10.1038/s41598-019-53872-1 · Cited by 24
Chen, H., Xia, B., Zheng, T., & Lou, G. (2019) · The International Journal of Biological Markers · doi:10.1177/1724600819888771 · Cited by 21
New biomarkers for checkpoint inhibitor therapy
Burdett, N. L., & Desai, J. (2020) · ESMO Open · doi:10.1136/esmoopen-2019-000597 · Cited by 25
Biomarkers for predicting the outcome of various cancer immunotherapies
Jafarzadeh, L., Khakpoor-Koosheh, M., Mirzaei, H., & Mirzaei, H. R. (2020) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2020.103161 · Cited by 22
Molecular and Immune Biomarkers for Cutaneous Melanoma: Current Status and Future Prospects
Pilla, L., Alberti, A., di Mauro, P., Gemelli, M. T., Cogliati, V., Cazzaniga, M. E., Bidoli, P., & Maccalli, C. (2020) · Cancers · doi:10.3390/cancers12113456 · Cited by 31
Zhao, R., Cao, L., Gu, W., Li, L., Chen, Z., Xiang, J., Zhou, Z.-Y., Xu, B., Zang, W., Zhou, X., et al. (2023) · Cell Reports Medicine · doi:10.1016/j.xcrm.2023.100953 · Cited by 28
Han, R. F., Zhang, Y., Wang, T., Xiao, H., Luo, Z., Shen, C., Li, J., Zhao, C., Li, L., Zhu, M., et al. (2022) · Cancer Science · doi:10.1111/cas.15778 · Cited by 23
Tian, J., & Quek, C. Y. J. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25084243 · Cited by 25
Kim, T. J., Hong, S. A., Kim, O., Kim, S. J., Yang, J., Joung, E. K., Kang, J., & Hong, S. H. (2017) · Oncotarget · doi:10.18632/oncotarget.22582 · Cited by 24
Clinical Perspectives of Single-Cell RNA Sequencing
Kim, N., Eum, H. H., & Lee, H. (2021) · Biomolecules · doi:10.3390/biom11081161 · Cited by 26
Predictive Biomarkers for PD-1 and PD-L1 Immune Checkpoint Blockade Therapy
Song, Y., Li, Z., Xue, W., & Zhang, M. (2019) · Immunotherapy · doi:10.2217/imt-2018-0173 · Cited by 22
Imperfect Predictors for Lung Cancer Immunotherapy—A Field for Further Research
Wojas‐Krawczyk, K., & Kubiatowski, T. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.568174 · Cited by 19
Santos-Briz, A. J., Cañueto, J., del Carmen, S., Barrios, B., Yuste‐Chaves, M., Bellido, L., de la Cruz, M. D. L., & Román, C. (2020) · American Journal of Dermatopathology · doi:10.1097/dad.0000000000001856 · Cited by 23
Zhang, B., Li, N., Gao, J., Zhao, Y., Jiang, J., Xie, S., Zhang, C., Zhang, Q., Liu, L., Wang, Z., et al. (2024) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-024-02974-4 · Cited by 24
Landwehr, L., Altieri, B., Sbiera, I., Remde, H., Kircher, S., Olabe, J., Sbiera, S., Kroiß, M., & Faßnacht, M. (2024) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgae109 · Cited by 20
Tumor inherent interferons: Impact on immune reactivity and immunotherapy
Brockwell, N. K., & Parker, B. S. (2018) · Cytokine · doi:10.1016/j.cyto.2018.04.006 · Cited by 21
Liu, D., Mehta, D., Kaur, S., Kumar, A., Parikh, K., Chawla, L., Patel, S., Devi, A., & Saha, A. (2018) · Journal of Hematology & Oncology · doi:10.1186/s13045-018-0682-5 · Cited by 22
Gide, T. N., da Silva, I. P., Quek, C. Y. J., Ferguson, P. M., Batten, M., Shang, P., Ahmed, T., Menzies, A. M., Carlino, M. S., Saw, R. P. M., et al. (2021) · Cancers · doi:10.3390/cancers13133186 · Cited by 23
Targeting KDM2A Enhances T-cell Infiltration in NSD1-Deficient Head and Neck Squamous Cell Carcinoma
Chen, C., Shin, J. H., Fang, Z., Brennan, K., Horowitz, N. B., Pfaff, K. L., Welsh, E. L., Rodig, S. J., Gevaert, O., Gozani, O., et al. (2023) · Cancer Research · doi:10.1158/0008-5472.can-22-3114 · Cited by 24
Immuno-oncology from the perspective of somatic evolution
González, S., Volkova, N. V., Beer, P. A., & Gerstung, M. (2017) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2017.12.001 · Cited by 23
Immunological and clinical implications of immune checkpoint blockade in human cancer
Kim, H., & Park, S. (2019) · Archives of Pharmacal Research · doi:10.1007/s12272-019-01140-1 · Cited by 22
Factors Determining Long-Term Antitumor Responses to Immune Checkpoint Blockade Therapy in Melanoma
Loo, K. L., Smithy, J. W., Postow, M. A., & Warner, A. B. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2021.810388 · Cited by 29
Self-citationHaugh, A. M., Salama, A. K. S., & Johnson, D. B. (2020) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2020.09.005 · Cited by 20
Gut microbiota in cancer initiation, development and therapy
Zhang, R., Zhang, X., Lau, H. C.-H., & Yu, J. Q. (2024) · Science China Life Sciences · doi:10.1007/s11427-024-2831-x · Cited by 19
Agha, D. M., Rouas, R., Najar, M., Bouhtit, F., Fayyad‐Kazan, H., Lagneaux, L., Bron, D., Meuleman, N., Lewalle, P., & Merimi, M. (2020) · Cells · doi:10.3390/cells9092053 · Cited by 23
Kumar, R., Thiagarajan, K., Jagannathan, L., Liu, L., Mayawala, K., de Alwis, D. P., & Topp, B. G. (2021) · CPT Pharmacometrics & Systems Pharmacology · doi:10.1002/psp4.12637 · Cited by 20
Georgoulias, G., & Zaravinos, A. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1006665 · Cited by 22
The Era of Checkpoint Blockade in Lung Cancer: Taking the Brakes Off the Immune System
Moon, E. K., Langer, C. J., & Albelda, S. Μ. (2017) · Annals of the American Thoracic Society · doi:10.1513/annalsats.201702-152fr · Cited by 20
Haku, Y., Kitaoka, K., Ichimaru, K., Hirano, T., Wang, J., Sonomura, K., Maruo, A., Hirose, S., Wang, Y., Ito, K., et al. (2026) · Nature Immunology · doi:10.1038/s41590-025-02370-w · Cited by 23
Biomarkers for Checkpoint Inhibition
Weber, J. S. (2017) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_175463 · Cited by 19
Melanoma: Prognostic Factors and Factors Predictive of Response to Therapy
Strudel, M., Festino, L., Vanella, V., Beretta, M., Marincola, F. M., & Ascierto, P. A. (2019) · Current Medicinal Chemistry · doi:10.2174/0929867326666191205160007 · Cited by 18
Overcoming Resistance to Immunotherapy in Advanced Cutaneous Squamous Cell Carcinoma
García‐Sancha, N., Corchado‐Cobos, R., Bellido-Hernández, L., Román‐Curto, C., Álvarez, E. C., Pérez‐Losada, J., Órfão, A., & Cañueto, J. (2021) · Cancers · doi:10.3390/cancers13205134 · Cited by 23
Cell Communication Network factor 4 promotes tumor‐induced immunosuppression in melanoma
Fernández, A., Deng, W., McLaughlin, S. L., Pirkey, A., Rellick, S. L., Razazan, A. P., & Klinke, D. J. (2022) · EMBO Reports · doi:10.15252/embr.202154127 · Cited by 19
Isomoto, K., Haratani, K., Tsujikawa, T., Makutani, Y., Kawakami, H., Takeda, M., Yonesaka, K., Tanaka, K., Iwasa, T., Hayashi, H., et al. (2022) · Lung Cancer · doi:10.1016/j.lungcan.2022.10.012 · Cited by 23
Althammer, S., Steele, K., Rebelatto, M., Tan, T.-H., Wiestler, T., Schmidt, G., Higgs, B., Li, X., Shi, L., Jin, X.-P., et al. (2016) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-016-0191-4 · Cited by 16
Okamura, H., Okazaki, I., Shimizu, K., Maruhashi, T., Sugiura, D., Mizuno, R., & Okazaki, T. (2019) · Journal of Autoimmunity · doi:10.1016/j.jaut.2019.06.007 · Cited by 20
Watson, G. A., Doi, J., Hansen, A. R., & Spreafico, A. (2020) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.14355 · Cited by 20
Mayer, A., Haist, M., Loquai, C., Grabbe, S., Rapp, M., Roth, W., Vaupel, P. W., & Schmidberger, H. (2020) · Cancers · doi:10.3390/cancers12123753 · Cited by 20
Hung, Y., Shao, Y., Lee, J., Hsu, C., Hsu, C., Yang, M., & Chao, Y. (2021) · Journal of the Chinese Medical Association · doi:10.1097/jcma.0000000000000477 · Cited by 17
CD8+ T Cell Subsets as Biomarkers for Predicting Checkpoint Therapy Outcomes in Cancer Immunotherapy
Casalegno‐Garduño, R., Spitschak, A., Pannek, T., & Pützer, B. M. (2025) · Biomedicines · doi:10.3390/biomedicines13040930 · Cited by 21
Co‐inhibitory blockade while preserving tolerance: checkpoint inhibitors for glioblastoma
Lucca, L. E., & Hafler, D. A. (2017) · Immunological Reviews · doi:10.1111/imr.12529 · Cited by 18
Skin Cancer: Genetics, Immunology, Treatments, and Psychological Care
Tavakolpour, S., Daneshpazhooh, M., & Mahmoudi, H. (2017) · Springer eBooks · doi:10.1007/978-3-319-64550-6_18 · Cited by 20
The host protecting the tumor from the host — targeting PD‑L1 expressed by host cells
Munn, D. H. (2018) · Journal of Clinical Investigation · doi:10.1172/jci99047 · Cited by 18
Downregulation of KEAP1 in melanoma promotes resistance to immune checkpoint blockade
Fox, D. B., Ebright, R. Y., Hong, X., Russell, H. C., Guo, H., LaSalle, T. J., Wittner, B. S., Poux, N., Vuille, J. A., Toner, M., et al. (2023) · npj Precision Oncology · doi:10.1038/s41698-023-00362-3 · Cited by 15
Prognostic and immunological significance of an M1 macrophage-related gene signature in osteosarcoma
Mao, X., Song, F., Jin, J., Zou, B., Dai, P., Sun, M., Xu, W., Wang, L., & Kang, Y. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1202725 · Cited by 17
Metadata
- Authors
- Daud, A. I., Loo, K., Pauli, M. L., Sanchez-Rodriguez, R., Sandoval, P. M., Taravati, K., Tsai, K., Nosrati, A., Nardo, L., Alvarado, M. D., Algazi, A. P., Pampaloni, M. H., Lobach, I. V., Hwang, J., Pierce, R. H., Gratz, I. K., Krummel, M. F., & Rosenblum, M. D.
- Affiliations
- UCSF Helen Diller Family Comprehensive Cancer Center (US)
- University of California, San Francisco (US)
- University of Salzburg (AT)
- Corresponding author
- Rosenblum, Michael D.
- ORCID
- Venue
- Journal of Clinical Investigation
- Published
- 2016-08-15
- Volume
- 126
- Issue
- 9
- Pages
- 3447-3452
- ISSN
- 0021-9738 (ISSN-L)
- 1558-8238
- PMC
- PMC5004965
- OpenAlex
- W2512255557
- Cited by
- 525
- References
- 23
- Citations by year
- 2026: 17 · 2025: 28 · 2024: 37 · 2023: 47 · 2022: 51 · 2021: 55 · 2020: 89 · 2019: 61 · 2018: 71 · 2017: 64 · 2016: 5
- FWCI
- 36.14
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Journal of Clinical Investigation (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- Funders
- International Business Machines Corporation
- National Institutes of Health (1dp2ar068130-01)
- University of California, San Francisco
- National Institute of Arthritis and Musculoskeletal and Skin Diseases (DP2-AR068130, R21AR066821, K08AR062064)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Keywords
- metastatic melanoma, anti-PD-1 therapy, immune checkpoint blockade, tumor immune profiling, CD8+ T cell exhaustion, tumor-infiltrating lymphocytes, predictive biomarkers, treatment response prediction, progression-free survival, regulatory T cells
- MeSH terms
- Biopsy, Female, Flow Cytometry, Humans, Immune System, Lymphocyte Activation, Male, Melanoma, Neoplasm Metastasis, Phenotype, Skin Neoplasms, Cohort Studies, T-Lymphocyte Subsets, Lymphocytes, Tumor-Infiltrating, Leukocyte Common Antigens, CD8-Positive T-Lymphocytes, Cell Line, Tumor, Tumor Microenvironment, CTLA-4 Antigen, Programmed Cell Death 1 Receptor, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.